| HOME >> BIOLOGY >> TECHNOLOGY |
WILMINGTON, Del., May 18 /PRNewswire/ -- HealthCore, Inc. is developing the Integrated Research Network (IRN(SM)) - a collaborative community of practicing physicians who participate in real-world prospective effectiveness research - in response to increasing need from industry and government to understand more about how drugs and medical devices are performing in patients in real-life settings.
To advance this understanding, HealthCore, the outcomes-based research subsidiary of WellPoint, Inc., is focusing on real-world prospective effectiveness research for healthcare interventions and continued evaluation of marketed drugs and medical devices. These real-world observational studies can be used to generate data about the clinical effectiveness, cost effectiveness and safety of products and devices.
"In the past, decision-makers have been challenged in obtaining applicable outcomes information, because of the artificial nature of findings derived from controlled clinical trials," said Mark Cziraky, HealthCore's vice president of research and development operations.
"HealthCore's research environment allows us to deliver information on how drugs and medical devices are used in the real world to follow patients over extended time periods and to integrate prospective, observational insights with retrospective data," Cziraky said. "The result is realistic, actionable information."
The demand for this kind of research is increasing--post-marketing research is the fastest growing drug development phase, estimated at $12 billion, and growing at 23 percent per year, according to a 2007 report from Research and Markets.
HealthCore will leverage the strengths of the Integrated Research Network--which generates real-world data from practicing physicians--the Healthcare Safety Sentinel System(TM) - a drug safety research system - and WellPoint's database of nearly 35 million members i
'/>"/>
| SOURCE HealthCore, Inc. Copyright©2009 PR Newswire. All rights reserved |